(Q38549208)

4 September 2017

title

The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines (English)

1 reference

4 September 2017

Thomas H Long

1

1 reference

4 September 2017

Helen Lawce

2

1 reference

4 September 2017

Connie Durum

3

1 reference

4 September 2017

Stephen R Moore

4

1 reference

4 September 2017

Susan B Olson

5

1 reference

4 September 2017

Ken Gatter

6

1 reference

4 September 2017

Megan L Troxell

7

1 reference

American Journal of Clinical Pathology

4 September 2017

language of work or name

English

1 reference

inferred from

publication date

1 August 2015

1 reference

American Journal of Clinical Pathology

4 September 2017

published in

1 reference

4 September 2017

volume

144

1 reference

4 September 2017

issue

2

1 reference

4 September 2017

page(s)

253-262

1 reference

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Reply to R. Bhargava et al and K. Lambein et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP3Q9WFOQTKUVV

21 January 2018

Identifiers

DOI

10.1309/AJCP3Q9WFOQTKUVV

1 reference

4 September 2017

1 reference